National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Apremilast (Otezla®) for psoriatic arthritis.

Apremilist (Otezla®), alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

Rapid Review

Commenced Completed Outcome
24/02/2015 03/04/2015 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/09/2015  29/04/2016 Reimbursement Not Recommended at the Submitted Price.


The HSE has approved reimbursement following confidential price negotiations October 2017.